Clinical Trials

Clinical-stage biotech company Aravax has announced that it has completed phase 2 recruitment for its precision therapy (PVX108) study, which investigates treatment of peanut allergies.

PVX108 is an advanced immunotherapy that is designed to reverse the course of allergic disease by retraining the immune system, according to the press release. This is done via the process of administering peptides that have been engineered to precisely target T-cells. This therapy contains no peanut proteins, reducing the risk of serious or harmful side effects in patients.

“The timely completion of recruitment across multiple sites in the US and Australia is a significant step for Aravax. There remains a critical need for better treatments for serious food allergies. PVX108 has been designed to provide a safe and convenient treatment that has the potential to reverse the course of allergic disease. We look forward to continuing evaluation of PVX108 efficacy in this potentially phase 3-enabling study,” commented Dr Pascal Hickey, CEO of Aravax.

Atotal of 95 patients aged four to 17 years have been enrolled in this double-blind placebo-controlled study, which is being conducted across eight sites in the US and six in Australia. The primary endpoint is to determine the maximum tolerated dose of peanut protein in a controlled food challenge at the end of the study period relative to the baseline. The study is being conducted under a US Food and Drug Administration (FDA) Investigational New Drug Application.